Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NBP vs SRZN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NBP Captures Overall Composite Edge (51.9 HOLD vs 32.8 SELL), While SRZN Leads 3–2 on Growth & Valuation Pillars

NBP Overall Winner 6-Pillar Tally: NBP 2 – 3 SRZN (1 Tie) Matrix Metrics: NBP 5 – 4 SRZN

As of Nov 16, 2026, NBP (NBP) captures the overall head-to-head institutional edge over Surrozen, Inc. Common (SRZN) on higher Unified Composite conviction (51.9/100 HOLD vs. 32.8/100 SELL) after splitting the core matrix 5–4 (led by Valuation Multiples, Profitability & Quality), while SRZN wins 3–2 across the 6-pillar growth and valuation breakdown. NBP trades at $0.79 (2.7x Forward P/E, 0.0% operating margin) versus SRZN at $32.80 (N/M Forward P/E, -485.4% operating margin).

  • Growth vs. Quality Trade-Off: NBP earns the overall head-to-head edge with a stronger Unified Composite Score (51.9/100 HOLD vs. SRZN 32.8/100 SELL) and 1.66β · 81% Vol risk profile, whereas SRZN leads top-line expansion (+408.6% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: NBP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 20.1); meanwhile SRZN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 62.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NBP vs SRZN
NBP US Equity Head-to-Head Winner
NBP
Institutional Equity
$0.79
-6.66% 1D
Market Cap $96.3M
TTM Revenue N/A
Forward P/E 2.7x
Beta / 30D Vol 1.66β · 81% Vol
Unified Composite Score
51.9 / 100 HOLD
Tech 60.0 Fund 50.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -19.4%), weak momentum, RSI 20
RSI-14: 20.1 · SMA20: $1.08 · SMA50: $1.31
SRZN NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$32.80
+3.76% 1D
Market Cap $603.7M
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.21β · 62% Vol
Unified Composite Score
32.8 / 100 SELL
Tech 50.0 Fund 32.0 Flow 64.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (10.1% over 20 days), RSI 63
RSI-14: 62.9 · SMA20: $29.54 · SMA50: $26.11

6-Pillar Scorecard Institutional Category Breakdown (NBP 2 – 3 SRZN)

Columns: Metric · NBP · SRZN
1. Valuation Multiples NBP
Forward P/E 2.7x N/M
Trailing P/E 2.7x N/M
PEG Ratio N/M N/M
EV / Revenue N/M 48.4x
2. Growth & Scale SRZN
Revenue Growth (YoY) +0.0% +408.6%
Earnings Growth (YoY) +0.0% -37.0%
TTM Revenue (USD) N/A $11M
Market Cap $96.3M $603.7M
3. Profitability & Quality NBP
Gross Margin N/A N/A
Operating Margin 0.0% -485.4%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -59.1% -62.8%
4. Balance Sheet & Cash Flow SRZN
Cash Generation (TTM) N/A -$31M
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.73 Book/Sh · -59.1% ROE $95M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SRZN
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 72.0% (5th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NBP (5) vs SRZN (4)
Institutional Metric NBP SRZN Criterion Row Edge
Market Capitalization
Scale
$96.3M $603.7M Larger Scale SRZN
Trailing P/E Ratio
Valuation
2.7x N/M Lower Multiple NBP
Forward P/E Ratio
Valuation
2.7x N/M Lower Multiple NBP
Revenue Growth (YoY)
Growth
+0.0% +408.6% Higher Growth SRZN
Operating Margin (TTM)
Profitability
0.0% -485.4% Higher Margin NBP
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-59.1% -62.8% Higher ROE NBP
52-Week Range Position
Momentum
0% ($1–$5) 80% ($12–$38) Stronger Trend SRZN
Beta / 30D Volatility
Risk Regime
1.66β · 81% Vol 1.21β · 62% Vol Lower Realized Risk SRZN
Unified Institutional Score
Composite Signal
51.9 / 100 (HOLD) 32.8 / 100 (SELL) Higher Composite NBP
Trailing 12M Revenue (USD)
Operating Scale
N/A $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 48.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($1.73 Book/Sh · -59.1% ROE) -$31M ($95M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SRZN +76.97 pp
NBP: -37.04% · SRZN: +39.93%
3M Horizon SRZN +94.7 pp
NBP: -58.03% · SRZN: +36.67%
6M Horizon SRZN +73.14 pp
NBP: -53.61% · SRZN: +19.53%
1Y Horizon SRZN +251.61 pp
NBP: -80.98% · SRZN: +170.63%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NBP vs SRZN. Trailing 12-month operating profitability (NBP 0.0% vs SRZN -485.4%) and valuation multiples (NBP 2.7x vs SRZN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

NBP ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-59.1% · 2.7x
SRZN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11M
Gross MarginN/A
Op. Margin-485.4%
ROE / Fwd P/E-62.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NBP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NBP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SRZN CONSOLIDATION
37d in phase · OBV NEUTRAL
Current IV 72.0%
IV Percentile 5th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SRZN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NBP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $96.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SRZN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $603.7M market capitalization and -485.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ NBP vs SRZN Key Questions & Quantitative Answers

As of Nov 16, 2026, NBP (NBP) captures the overall head-to-head institutional edge over Surrozen, Inc. Common (SRZN) on higher Unified Composite conviction (51.9/100 HOLD vs. 32.8/100 SELL) after splitting the core matrix 5–4 (led by Valuation Multiples, Profitability & Quality), while SRZN wins 3–2 across the 6-pillar growth and valuation breakdown. NBP trades at $0.79 (2.7x Forward P/E, 0.0% operating margin) versus SRZN at $32.80 (N/M Forward P/E, -485.4% operating margin). Growth vs. Quality Trade-Off: NBP earns the overall head-to-head edge with a stronger Unified Composite Score (51.9/100 HOLD vs. SRZN 32.8/100 SELL) and 1.66β · 81% Vol risk profile, whereas SRZN leads top-line expansion (+408.6% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: NBP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 20.1); meanwhile SRZN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 62.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SRZN leads the Growth & Scale pillar: NBP posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with SRZN at +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin). On trailing 12-month operating scale, NBP generates N/A in USD-normalized revenue versus $11M for SRZN. In operating R&D and SG&A reinvestment, NBP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SRZN.

NBP screens cheaper on headline valuation multiples. NBP trades at 2.7x Forward P/E, 2.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 48.4x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NBP (-59.1% ROE) versus SRZN (-62.8% ROE) capital efficiency.

In options market volatility and institutional positioning, NBP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.66β · 81% Vol realized risk). By comparison, SRZN carries 72.0% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.21β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.